- Service Name
Iovance Biotherapeutics
- Industry
Healthcare, Biotechnology, Cancer Treatment, Immunotherapy
- Main Value Proposition
Iovance Biotherapeutics offers personalized cancer therapies that harness the power of the immune system to effectively combat various types of cancer.
- Description
Iovance Biotherapeutics is focused on developing innovative cancer treatments through tumor infiltrating lymphocyte (TIL) therapy and peripheral blood lymphocyte (PBL) therapy. These therapies utilize the patient's own immune cells to target and attack cancer cells effectively.
- Key Features
Utilizes patient-specific TIL to target diverse cancer cells; Investigational therapies designed to reinvigorate immune response; State-of-the-art manufacturing at the Iovance Cell Therapy Center; Focus on both solid tumors and blood cancers
- Use Cases
The service is most valuable for patients with advanced solid tumors and blood cancers who are seeking innovative and personalized treatment options.
- Competitive advantages
Personalized treatment based on individual patient immune profiles; Innovative use of TIL therapy for advanced solid tumors; State-of-the-art manufacturing capabilities ensuring high-quality therapy production
- Strengths
Iovance Biotherapeutics stands out for its pioneering research in TIL therapy, robust clinical trial pipeline, and commitment to leveraging cutting-edge technology in cancer treatment.
- Positioning
Iovance positions itself as a leader in the field of personalized cancer immunotherapy, focusing on innovative treatments that utilize the body's own immune system.
- Audience
The target users include cancer patients, oncologists, and healthcare providers looking for advanced immunotherapy options.
- CTA
Learn more about TIL therapy
- Tags
Cancer Treatment
Immunotherapy
Personalized Medicine
Clinical Trials
- Tagline
Pioneering a Transformational Approach to Treating Cancer
- Tone of Voice
Innovative, authoritative, compassionate
- Differentiation
The service is unique in its approach of using polyclonal T cells that target a variety of neoantigens specific to each patient's tumor, unlike traditional therapies that focus on shared antigens.
- Brand Positioning
The brand is identified as a pioneering and transformative force in cancer treatment, emphasizing innovation, personalization, and scientific rigor.
- Founded
2007-01-01
- Founders
Manish Singh